Clinical trials: Transthyretin Amyloid Cardiomyopathy
Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM)
Study of AG10 in Amyloid Cardiomyopathy
This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK (Pharmacokinetic) and PD (Pharmacodynamic) of AG10 compared to placebo…
- Trial name
- NCT03458130
- Testing
- AG10
- Where
- 13 sites in United States
- Volunteers
- 49 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Transthyretin Amyloidosis
Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since…
- Trial name
- NCT05635045
- Testing
- I 124-Evuzamitide
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Columbia University
TTR Cardiac Amyloidosis
A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin
Cardiac amyloidosis caused by transthyretin either mutated (in ATTRm amyloidosis) or wildtype (in ATTRwt, formerly senile, amyloidosis) is a rare disease but is diagnosed with increasing frequency thanks to the availability of…
- Trial name
- NCT03481972
- Testing
- Doxycycline and tauroursodeoxycholic acid, Standard of care
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Hereditary Transthyretin-mediated Amyloidosis With Polyneropathy, Pregnancy
TEGSEDI Pregnancy Surveillance Program
This is a worldwide safety surveillance study of pregnancy outcomes in women with hATTR-PN who may have been exposed or were not exposed to TEGSEDI prior to or during the pregnancy and of pediatric outcomes up to 1 year of age.
- Trial name
- NCT04270058
- Testing
- inotersen
- Volunteers
- 20 people
- Sponsor
- Akcea Therapeutics
Transthyretin (TTR) Amyloid Cardiomyopathy
Vyndaqel Capsules Special Investigation (ATTR-CM)
Secondary Data Collection : To confirm the safety and effectiveness profiles under the actual medical practice of Vyndaqel in Japan.
- Trial name
- NCT04108091
- Testing
- Treatment for TTR amyloidosis
- Where
- Japan
- Volunteers
- 1,214 people
- Sponsor
- Pfizer
Amyloidosis, Cardiomyopathy
Carpal Tunnel Syndrome and Amyloid Cardiomyopathy
The investigators will prospectively evaluate tissue samples obtained from patients undergoing carpal tunnel release surgery for amyloid in the soft tissue that is removed.
- Conditions
- Amyloidosis, Cardiomyopathy, Transthyretin Amyloidosis, Senile Systemic Amyloidosis
- Trial name
- NCT02792790
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- The Cleveland Clinic
Transthyretin Cardiac Amyloidosis
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin…
- Trial name
- CONCERTO (NCT06978660)
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 2,200 people
- Sponsor
- Idoven 1903 S.L.
ATTR Amyloidosis Wild Type
Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)
The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt).
- Trial name
- DobATTR (NCT06318260)
- Testing
- Dobutrex
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Steen Hvitfeldt Poulsen
Amyloidosis; Systemic, Amyloidosis Cardiac
Essen Amyloidosis Registry
The Essen Amyloidosis Registry (EAR) is a prospective, observational registry designed to collect comprehensive clinical data on patients diagnosed with systemic amyloidosis.
- Trial name
- EAR (NCT06887283)
- Where
- Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Amyloid Neuropathies, Transthyretin Amyloidosis
Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study
Familial amyloid neuropathies (FAP) are hereditary disease due to a mutation of the tranthyretin gene (TTR). These neuropathies are severe and life frightening.
- Trial name
- NCT03588468
- Testing
- Electrophysiological biomarkers, MRI biomarkers
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Transthyretin Cardiac Amyloidosis
Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach
Transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved ejection fraction. Its diagnosis is currently based on a non-invasive method including biology and imaging.
- Trial name
- ATTR-AI (NCT05772091)
- Where
- 4 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Pr. Nicolas GIRERD
ATTR Amyloidosis With Cardiomyopathy, ATTR-CM
A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.
The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral (MR) and tricuspid regurgitation (TR) in patients…
- Conditions
- ATTR Amyloidosis With Cardiomyopathy, ATTR-CM, ATTR Amyloidosis Wild Type, Mitral Regurgitation
- Trial name
- NCT06836011
- Where
- 8 sites in Austria, Germany and 2 more
- Volunteers
- 600 people
- Sponsor
- Medical University of Vienna
Transthyretin Amyloidosis, Cardiomyopathy
Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis
The primary objective for this study is to evaluate the efficacy of doxycycline + ursodeoxycholic acid (UDCA) on disease progression in Transthyretin Amyloidosis (ATTR) subjects with cardiomyopathy with or without neuropathy.
- Trial name
- Dox/Urso (NCT02016365)
- Testing
- Doxycycline, Ursodeoxycholic acid
- Where
- 3 sites in Sweden
- Volunteers
- 55 people
- Sponsor
- Umeå University
Transthyretin Amyloidosis, Transthyretin Amyloidosis With Cardiomyopathy
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
The aim of this observational cohort study is to characterise use of eplontersen in patients with prior liver transplant or with pre-existing severe hepatic impairment, as well as to assess long-term safety among all new users of…
- Conditions
- Transthyretin Amyloidosis, Transthyretin Amyloidosis With Cardiomyopathy, Transthyretin Amyloidosis With Polyneuropathy
- Trial name
- sTTRing (NCT07654855)
- Testing
- None ( observational study )
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Wild-type Transthyretin Amyloidosis
Prevalence of Wild Type ATTR
Prospective, observational, single-centre, non-interventional study aiming at reporting the prevalence of ATTRwt in patients with lumbar spinal stenosis (LSS).
- Trial name
- NCT03966105
- Testing
- HE and Congo red staining
- Where
- Switzerland
- Volunteers
- 94 people
- Sponsor
- Oncology Institute of Southern Switzerland
Transthyretin Amyloidosis
New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis
The development of cardiac amyloidosis is caused by the deposition of misfolded, insoluble proteins in the extracellular matrix of tissues.
- Trial name
- NCT06345235
- Testing
- blood test
- Where
- Poland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- John Paul II Hospital, Krakow
Heart Disease, Aging
Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.
Background: The prevalence of both senile cardiac amyloidosis (CA) and aortic stenosis (AS) markedly increases with age. Aortic stenosis increases left ventricular pressure overload.
- Conditions
- Heart Disease, Aging, Amyloidosis, Aortic Valve Stenosis
- Trial name
- AMYLOCARTESIAN (NCT02260466)
- Testing
- a basal LV septum biopsy
- Where
- 5 sites in France
- Volunteers
- 186 people
- Sponsor
- French Cardiology Society
Transthyretin Amyloid Cardiomyopathy, Aortic Stenosis
Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy
The goal of this prospective clinical study is to improve the diagnosis of Low-flow low-gradient aortic stenosis (LF/LG AS), in patients with co-existing wild-type transthyretin cardiac amyloidosis (ATTRwt).
- Trial name
- DobAttrAS (NCT06372301)
- Testing
- Dobutamine stress echocardiography
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Steen Hvitfeldt Poulsen
Transthyretin Amyloidosis
Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis
This study is being conducted to explore the potential benefits of a twelve-month doxycycline (at the best tolerated dose of 200 mg/day) and tauroursodeoxycholic acid (750 mg/day) treatment on disease progression in patients…
- Trial name
- NCT01171859
- Testing
- Doxycycline + Tauroursodeoxycholic acid
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Amyloid Cardiomyopathy
Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy
This Phase 1b/2a study aims to investigate the safety and efficacy of genistein in patients with Transthyretin (TTR) Amyloidosis.
- Trial name
- GASPAR (NCT06634108)
- Testing
- Genistein
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's